{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:53Z","timestamp":1794048893450,"version":"4.8.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>This non-interventional post-authorisation safety study (PASS) assessed the long-term safety of everolimus in patients with tuberous sclerosis complex (TSC) who participated in the TuberOus SClerosis registry to increase disease Awareness (TOSCA) clinical study and received everolimus for the licensed indications in the European Union. The rate of adverse events (AEs), AEs that led to dose adjustments or treatment discontinuation, AEs of potential clinical interest, treatment-related AEs (TRAEs), serious AEs (SAEs), and deaths were documented. One hundred seventy-nine patients were included in the first 5 years of observation; 118 of 179 patients had an AE of any grade, with the most common AEs being stomatitis (7.8%) and headache (7.3%). AEs caused dose adjustments in 56 patients (31.3%) and treatment discontinuation in nine patients (5%). AEs appeared to be more frequent and severe in children. On Tanner staging, all patients displayed signs of age-appropriate sexual maturation. Twenty-two of 106 female (20.8%) patients had menstrual cycle disorders. The most frequent TRAEs were stomatitis (6.7%) and aphthous mouth ulcer (5.6%). SAEs were reported in 54 patients (30.2%); the most frequent SAE was pneumonia (&amp;gt;3% patients; grade 2, 1.1%, and grade 3, 2.8%). Three deaths were reported, all in patients who had discontinued everolimus for more than 28 days, and none were thought to be related to everolimus according to the treating physicians. The PASS sub-study reflects the safety and tolerability of everolimus in the management of TSC in real-world routine clinical practice.<\/jats:p>","DOI":"10.3389\/fneur.2021.630378","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T06:33:19Z","timestamp":1616481199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex"],"prefix":"10.3389","volume":"12","author":[{"given":"J. Chris","family":"Kingswood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Belousova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana P.","family":"Benedik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Curatolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume B.","family":"d'Aug\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fladrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Macaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finbar","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Touraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Youroukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zonnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TOSCA Consortium and TOSCA Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejpn.2015.11.011","article-title":"The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)","volume":"20","author":"Kingswood","year":"2016","journal-title":"Eur J Paediatr Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"International Tuberous Sclerosis Complex Consensus. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 Study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajmg.c.31654","article-title":"Renal manifestation of tuberous sclerosis complex","volume":"178","author":"Bissler","year":"2018","journal-title":"Am J Med Genet C Sem Med Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations","volume":"17","author":"Jozwiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-014-0182-9","article-title":"TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex","volume":"9","author":"Kingswood","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience","volume":"22","author":"Krueger","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","article-title":"Prevalence of tuberous sclerosis estimated by capture-recapture analysis","volume":"351","author":"FJ","year":"1998","journal-title":"The Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","volume":"68","author":"Sadowski","year":"2016","journal-title":"Pharmacol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ajmg.c.31655","article-title":"mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex","volume":"178","author":"Franz","year":"2018","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.630378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T06:33:22Z","timestamp":1616481202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.630378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":22,"alternative-id":["10.3389\/fneur.2021.630378"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.630378","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"article-number":"630378"}}